Reviva Pharmaceuticals Holdings (RVPH) Update / Briefing June 02, 2025 08:00 AM ET Speaker0 As a reminder, this call is being recorded, and a replay will be made available on the Reviva website following the conclusion of the event. I'd now like to turn the call over to doctor Lax Bhatt, founder, president, and chief executive officer of Reviva Pharmaceuticals. Please go ahead, Lax. Speaker1 Thank you, Tara. So good morning, everyone. My name is Lax Bart. I am the founder, president, and CEO of Reviva Pharm ...

Reviva Pharmaceuticals Reviva | Corporate Presentation 3 Phase 3 RECOVER Open-Label Extension (OLE) Trial of Brilaroxazine in Schizophrenia June 2, 2025 at 8:00am EDT Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's expectations regarding the anticipate ...

– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects – – Virtual investor webcast today at 8:00 a.m. EDT – CUPERTINO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage p ...

Summary of Reviva Pharmaceuticals Holdings (RVPH) Conference Call Company Overview - **Company**: Reviva Pharmaceuticals Holdings (RVPH) - **Industry**: Pharmaceuticals, specifically focused on neuropsychiatric disorders - **Key Product**: Duloxazine, currently in phase three development for schizophrenia Core Points and Arguments 1. **Pipeline Development**: Reviva is developing next-generation therapies for neuro dysfunction, with Duloxazine being the most advanced molecule aimed at treating schizophrenia and potentially other psychiatric conditions such as bipolar disorder, major depressive disorder, and ADHD [4][5] 2. **Market Potential**: The indications targeted by Reviva represent a multibillion-dollar market, with over 24 million people suffering from schizophrenia globally, and around 4 million in the US alone [7][8] 3. **Unmet Needs**: Approximately 30% of schizophrenia patients do not respond to current treatments, highlighting the need for better options that address negative symptoms and treatment adherence [8][10] 4. **Efficacy and Safety**: Duloxazine has shown a 12-16% discontinuation rate in trials, significantly lower than the 30-70% seen with existing antipsychotics, indicating better treatment adherence [12][26] 5. **Neuroinflammation**: The drug also targets neuroinflammation, which is a significant factor in disease progression and comorbidities in psychiatric patients [9][21] 6. **Phase Three Data**: The pivotal phase three study involved 411 patients and demonstrated a statistically significant outcome with a 10-point separation from placebo, indicating robust efficacy [14][15] 7. **Negative Symptoms**: Duloxazine showed a 2-point separation in negative symptoms, a chronic condition that is difficult to treat, with only a few existing drugs demonstrating significant outcomes [17][20] 8. **Biomarkers**: The use of digital biomarkers, such as speech patterns, has confirmed the drug's efficacy in patients with severe negative symptoms [19][24] 9. **Safety Profile**: The safety profile of Duloxazine is comparable to placebo, with minimal motor side effects and manageable weight gain, which is often a concern with antipsychotics [26][27] 10. **Future Development**: Reviva plans to initiate a second phase three study (RECOVER 2) to further support the NDA submission, expected by the end of next year [34][43] Additional Important Content - **Mechanism of Action**: Duloxazine directly modulates dopamine and serotonin receptors, addressing both behavioral symptoms and inflammatory cascades, which differentiates it from existing treatments [39][40] - **Long-term Efficacy**: Data from long-term studies indicate sustained efficacy and safety, with dropout rates significantly lower than those of other antipsychotics [31][32] - **Regulatory Pathway**: The company is on track to meet the requirements for NDA submission, having completed necessary trials and safety studies [42][43] This summary encapsulates the key points discussed during the conference call, highlighting Reviva Pharmaceuticals' strategic focus on addressing significant unmet needs in the treatment of schizophrenia and related disorders.

CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following upcoming investor conferences. Benchmark Healthcare House Call Virtual I ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☒ 1934 For the quarterly period ended March 31, 2025 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ For the transition period from ____ to ____ Not applicable (Former name, former address and former fiscal year, if changed since last report) Commission file number: 001-38634 ...

Exhibit 99.1 Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights – 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment – – Full data set from RECOVER OLE highlighting clinical response, safety, ef icacy, adherence, and biomarker data expected in Q2 2025 – Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Secti ...

– 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment – – Full data set from RECOVER OLE highlighting clinical response, safety, efficacy, adherence, and biomarker data expected in Q2 2025 – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 – CUPERTINO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “ ...

Reviva Pharmaceuticals Holdings (RVPH) 2025 Conference May 08, 2025 10:30 AM ET Speaker0 Here this morning at the Citizens Life Science Conference. Excited to be joined next by Reviva Pharmaceuticals. Reviva is a company focused on novel treatments for neuropsychiatric diseases. Really glad to be joined by the company's CEO, Laxbot. Lax, thank you for being here. Lax is going to run through a few slides and then we'll jump into Q and A. Speaker1 Yep, thanks. Thanks, Jason. Thanks for having me here. So I re ...

CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Citizens Life Sciences Conference, taking place May 7-8, 2025, in New York, NY. Revi ...